Protalix BioTherapeutics Inc. (AMEX: PLX) started the day on September 09, 2021, with a price decrease of -1.76% at $1.67. During the day, the stock rose to $1.77 and sunk to $1.66 before settling in for the price of $1.70 at the close. Taking a more long-term approach, PLX posted a 52-week range of $1.30-$7.02.
Nevertheless, stock’s Earnings Per Share (EPS) this year is -168.20%. This publicly-traded company’s shares outstanding now amounts to $45.38 million, simultaneously with a float of $34.67 million. The organization now has a market capitalization sitting at $75.79 million. At the time of writing, stock’s 50-day Moving Average stood at $1.5740, while the 200-day Moving Average is $3.3748.
While finding the extent of efficiency of the company that is accounted for 207 employees. It has generated 303,855 per worker during the last fiscal year. Meanwhile, its income per employee was -31,512. The stock had 18.78 Receivables turnover and 1.11 Total Asset turnover. For the Profitability, stocks gross margin was +82.71, operating margin was +4.31 and Pretax Margin of -10.37.
Protalix BioTherapeutics Inc. (PLX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Protalix BioTherapeutics Inc.’s current insider ownership accounts for 22.48%, in contrast to 20.94% institutional ownership. According to the most recent insider trade that took place on Jun 03, this organization’s 10% Owner sold 857,506 shares at the rate of 2.25, making the entire transaction reach 1,932,304 in total value, affecting insider ownership by 3,637,314. Preceding that transaction, on Jun 02, Company’s 10% Owner sold 61,211 for 2.56, making the whole transaction’s value amount to 156,553. This particular insider is now the holder of 4,494,820 in total.
Protalix BioTherapeutics Inc. (PLX) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 6/29/2021, the organization reported -$0.25 earnings per share (EPS) for the three months, lower than the consensus estimate (set at -$0.08) by -$0.17. This company achieved a net margin of -10.37. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.
Protalix BioTherapeutics Inc.’s EPS decrease for this current 12-month fiscal period is -168.20% and is forecasted to reach 0.04 in the upcoming year.
Protalix BioTherapeutics Inc. (AMEX: PLX) Trading Performance Indicators
Let’s observe the current performance indicators for Protalix BioTherapeutics Inc. (PLX). The Stock has managed to achieve an average true range (ATR) of 0.09. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.44.
In the same vein, PLX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.39, a figure that is expected to reach -0.08 in the next quarter, and analysts are predicting that it will be 0.04 at the market close of one year from today.
Technical Analysis of Protalix BioTherapeutics Inc. (PLX)
If we take a close look at the recent performances of Protalix BioTherapeutics Inc. (AMEX: PLX), its last 5-days Average volume was 2.01 million that shows progress from its year to date volume of 1.44 million. During the previous 9 days, stock’s Stochastic %D was recorded 75.79% While, its Average True Range was 0.0989.
Raw Stochastic average of Protalix BioTherapeutics Inc. (PLX) in the period of the previous 100 days is set at 6.93%, which indicates a major fall in contrast to 77.08% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 43.09% that was lower than 66.35% volatility it exhibited in the past 100-days period.